Alexandro Membrino

DPYD -Guided Dosing of Metronomic Capecitabine Plus Vinorelbine in Metastatic Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: A Real-World Retrospective Study

Francesco Schettini, Alexandro Membrino, G Grazia, Aldo Caltavituro et autres

PURPOSE Metronomic chemotherapy with oral capecitabine + vinorelbine (Cape + VNL) provides synergistic cytostatic activity and antiangiogenic and immunomodulatory effects, potentially offering prolonged disease control with limited toxicity in HER2-negative metastatic breast cancer (MBC). However, efficacy in the real-world (RW) setting, especially …

es, it, jp (code pays fourni par la source)

A mixed prebiotic/probiotic intervention (MBR-01) for the management of diarrhea during abemaciclib treatment of early breast cancer in postmenopausal patients: A single-center prospective case–control pilot study

Daniele Generali, Alexandro Membrino, Alessandra Fontana, Federica Gattazzo et autres

BACKGROUND: Adjuvant abemaciclib + endocrine therapy (ET) improves long-term outcomes in high-risk, hormone receptor-positive (HR+)/HER2-negative early breast cancer (eBC). However, treatment is frequently complicated by diarrhea, affecting adherence and quality-of-life (QoL). Increasing evidence suggests that abemaciclib-induced gastrointestinal toxicity may involve gut microbiota …

it, us, es (code pays fourni par la source)

Validation of a large language model as a decision tool for drug interaction in prostate cancer: A comparative study against UpToDate. Meet-URO 5/25 - GENIE study

Simone Rota, Alberto E. Tozzi, Martina Fanelli, Arianna Dri et autres

it (code pays fourni par la source)

Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study

Maria Gemelli, Luca Sala, Alessandro Morabito, Vincenzo Sforza et autres

it (code pays fourni par la source)

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

Maria Gemelli, Luca Sala, Alessandro Morabito, Vincenzo Sforza et autres

it (code pays fourni par la source)

A Mixed Probiotic/Prebiotic Intervention (MBR-01) for the Management of Diarrhea During Abemaciclib Treatment of Early Breast Cancer: A Single-Center Prospective Case–Control Pilot Study

D. Generali, Alexandro Membrino, Alessandra Fontana, Federica Gattazzo et autres

Abstract Background Adjuvant abemaciclib+endocrine therapy (ET) improves long-term outcomes in high-risk, hormone receptor–positive (HR+)/HER2-negative early breast cancer (eBC). However, treatment is frequently complicated by diarrhea, affecting adherence and quality of life (QoL). Increasing evidence suggests that abemaciclib-induced gastrointestinal toxicity may involve gut …

it, es, us (code pays fourni par la source)

Real-World Effectiveness of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A Systematic Comparison with Randomised Controlled Trial Data Using a Digital Twin Approach

Daniele Generali, Francesco Riccetelli, Alexandro Membrino, See PDF

Reproducible Code and Data for Absolute-Benefit Simulation Study

Alberto D’Angelo, Francesco Riccitelli, Carla Strina, Manuela Milani et autres

Complete Python code, fitted parameters, modelling assumptions, and synthetic patient-level datasets supporting the analyses reported in the manuscript. All analyses use a fixed random seed for reproducibility.

gb, it (code pays fourni par la source)

Reproducible Code and Data for Absolute-Benefit Simulation Study

Alberto D’Angelo, Francesco Riccitelli, Carla Strina, Manuela Milani et autres

Complete Python code, fitted parameters, modelling assumptions, and synthetic patient-level datasets supporting the analyses reported in the manuscript. All analyses use a fixed random seed for reproducibility.

gb, it (code pays fourni par la source)

Immune biomarkers for head and neck cancer

Navid Sobhani, Alberto D’Angelo, Fernanda G. Kugeratski, Tristan Nguyen et autres

In recent years, head and neck cancer therapy has been revolutionized by immunotherapy, which aims to restore the immune system's anticancer activity suppressed by cancer cells. The major concern is that only a subset of patients responds to this therapy. Having specific …

us, gb, it (code pays fourni par la source)

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era

Alexandro Membrino, Carol Zanchetta, Simona Rizzato, Francesco Cortiula et autres

Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS) enables comprehensive genetic profiling of tumours, including non-driver alterations that offer …

it, nl (code pays fourni par la source)

Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study

Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, Ferdinando Riccardi et autres

BACKGROUND: Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET). PATIENTS AND METHODS: The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 …

be, it (code pays fourni par la source)